Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cosmin Dascalu"'
Autor:
Meyha Sahin, Mesut Yilmaz, Ali Mert, Ahmet Naci Emecen, Muna A. Rahman S. Al Maslamani, Samar Mahmoud A. Hashim, Ajithkumar Valooparambil Ittaman, Jamal Wadi Al Ramahi, Balint Gergely Szabo, Deborah Konopnicki, Dilsah Baskol Elik, Botond Lakatos, Oguz Resat Sipahi, Reham Khedr, Sabah Jalal, Natalia Pshenichnaya, Dumitru Irina Magdalena, Amani El-Kholy, Ejaz Ahmed Khan, Sevil Alkan, Atousa Hakamifard, Gulden Sincan, Aliye Esmaoglu, Mateja Jankovic Makek, Esra Gurbuz, Anna Liskova, Ayse Albayrak, Roman Stebel, Tulay Unver Ulusoy, Rezaul Karim Ripon, Ruxandra Moroti, Cosmin Dascalu, Naveed Rashid, Andrea Cortegiani, Zeynep Bahadir, Hakan Erdem
Publikováno v:
Heliyon, Vol 10, Iss 14, Pp e34325- (2024)
Background: This study aimed to identify factors that influence the mortality rate of patients with coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA). Methods: In this cross-sectional study, data from 23 centers across 15 count
Externí odkaz:
https://doaj.org/article/ce62be361fb84e91a4a6dadf62e43d77
Autor:
Meggan Mackay, Tam Quach, Weiqing Huang, Zheng Liu, Martin Lesser, Tungming Leung, Jian Han, Cynthia Aranow, Thomas L. Rothstein, Richard A. Furie, Cosmin Dascalu, Anne Davidson
Publikováno v:
Adaptive Immunity.
Background Belimumab has a therapeutic benefit in active SLE, especially in patients with high titers of anti-dsDNA antibodies. The current study was designed to address whether the profound loss of naive B cells in belimumab treated patients is acco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1df48f0586b51b47239125b737d26af
https://doi.org/10.1136/lupus-2018-lsm.18
https://doi.org/10.1136/lupus-2018-lsm.18
Autor:
Jian Han, Richard Furie, Weiqing Huang, Zheng Liu, Tam D. Quach, Anne Davidson, Tungming Leung, Qunying Yang, Wenjing Pan, Cosmin Dascalu, Cynthia Aranow, Miranda Byrne-Steele, Thomas L. Rothstein, Meggan Mackay, Martin Lesser
Publikováno v:
JCI insight. 3(17)
Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially in patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss in belimumab-treated SLE patients is accompanied by shifts in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b31305410ed387d552191edf752237
https://pubmed.ncbi.nlm.nih.gov/30185675
https://pubmed.ncbi.nlm.nih.gov/30185675
Publikováno v:
Journal of Clinical Rheumatology. 19:297-299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e59c0b9e0caffe405b9ca6d9740b7e7
https://doi.org/10.1097/rhu.0b013e31828c3d73
https://doi.org/10.1097/rhu.0b013e31828c3d73